Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism

Deborah Y. Park, BS, Shyam K. Poudel, MD, Xuefei Jia, MS, Mailey Lynn Wilks, CNP, MSN, APRN, Vicki Pinkava, MSBS, PA-C, Meghan O'Brien, MS, ANP-BC, Barbara Tripp, CNS,AOCN, Jung-Min Song, RN,CNS, Keith R. McCrae, MD, Dana E. Angelini, MD, Alok A. Khorana, MD

Blood (2018) 132 (Supplement 1): 1237.

https://doi.org/10.1182/blood-2018-99-111897

Published: 2018

Journal Articles

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, Heather A. Rasmussen, BS, Pamela S. Becker, MD, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2018-99-115476

Published: 2018

Journal Articles

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2018) 132 (Supplement 1): 955.

https://doi.org/10.1182/blood-2018-99-110548

Published: 2018

Journal Articles

Folate-Dependent Normocytic Anemia Caused By a Hypomorphic Mutation in SLC19A1 gene

Michael Svaton, MD, Karolina Skvarova Kramarzova, MSc, PhD, Veronika Kanderova, MSc, PhD, Petr Smisek, MD, Pavel Jesina, MSc, MD, PhD, Jakub Krijt, MSc, Blanka Stiburkova, MSc, PhD, Andrea Mancikova, MSc, Robert Dobrovolny, MSc, PhD, Violeta Bakardjieva-Mihaylova, MSc, Elena Vodickova, MD, Jan Stuchly, MSc, Tomas Kalina, MD PhD, Jan Stary, MD PhD, Jan Trka, MD PhD, Eva Fronkova, MD PhD, Viktor Kozich, MD PhD

Blood (2018) 132 (Supplement 1): 502.

https://doi.org/10.1182/blood-2018-99-113501

Published: 2018

Journal Articles

Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis

Marta Davidson, MDPhD, Douglas A. Stewart, Peter Duggan, MD FRCPC, Andrew Daly, MD, Mona Shafey, MD

Blood (2017) 130 (Supplement 1): 4534.

https://doi.org/10.1182/blood.V130.Suppl_1.4534.4534

Published: 2017

Journal Articles

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Marina Motta, MD, Marco Chiarini, MSC, Marta Petullà, PharmD, Claudia Ghidini, BSC, Marion Vaglio Tessitore, BSC, Viviana Giustini, MSC, Chiara Pagani, MD, Antonella Anastasia, MD, Samantha Ferrari, MD, Alessandra Tucci, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 1531.

https://doi.org/10.1182/blood.V126.23.1531.1531

Published: 2015

Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Blood (2015) 126 (23): 1361.

https://doi.org/10.1182/blood.V126.23.1361.1361

Published: 2015

Journal Articles

Erlotinib Is Not Effective In Patients (Pts) With JAK-2 V617F Positive Polycythemia Vera

Mohamad Cherry, MD, Mohamad Khawandanah, MD, Zhizhuang Joe Zhao, Samer A Srour, MB ChB, Howard Ozer, MD, PhD, George Selby, MD, Bassam Ghabache, MD, Aref Al-Kali, MD

Blood (2013) 122 (21): 1597.

https://doi.org/10.1182/blood.V122.21.1597.1597

Published: 2013

Journal Articles

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Marina Konopleva, MD, PhD, Damian R Handisides, Mary Ann Richie, RN, Juliana M Benito, PhD, Gautam Borthakur, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, Jorge E. Cortes, MD, Stewart Kroll, Michael Andreeff, MD, PhD, Hagop M Kantarjian, MD, Deborah A. Thomas, MD

Blood (2013) 122 (21): 3920.

https://doi.org/10.1182/blood.V122.21.3920.3920

Published: 2013

Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 2959.

https://doi.org/10.1182/blood.V120.21.2959.2959

Published: 2012

Journal Articles

Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Ali M Al-Ameri, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD, Elizabeth Burton, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Xavier Badoux, MD, Susan O'Brien, Gloria Mattiuzzi, MD

Blood (2010) 116 (21): 1233.

https://doi.org/10.1182/blood.V116.21.1233.1233

Published: 2010

Journal Articles

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, Monica Grazziutti, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 368.

https://doi.org/10.1182/blood.V116.21.368.368

Published: 2010

Journal Articles

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Leslie A. Andritsos, MD, Beth Fischer, R.N., Thomas S. Lin, M.D., Kristie A. Blum, M.D., Jeffrey A. Jones, M.D., Mollie E. Moran, C.N.P., John C. Byrd, M.D., Michael R. Grever, M.D.

Blood (2007) 110 (11): 3128.

https://doi.org/10.1182/blood.V110.11.3128.3128

Published: 2007

Journal Articles

Multiple Myeloma Presenting as Pulmonary, Gastric and Epidural Extramedullary Plasmacytomas: Synchronous Presentation.

Maged Khalil, MD, Candice Ruby, MD, Zili He, MD, Shetra Sivamurthy, MD, Steier Williams, MD, Madhumati Kalavar, MD

Blood (2005) 106 (11): 5050.

https://doi.org/10.1182/blood.V106.11.5050.5050

Published: 2005

Journal Articles

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. De Angelo, Thomas Shea, Wendy Stock, Vera Hars, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson

Blood (2005) 106 (11): 407.

https://doi.org/10.1182/blood.V106.11.407.407

Published: 2005

Journal Articles

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

Jorge Cortes, M.D., Guillermo Garcia-Manero, M.D., Susan O’Brien, M.D., Ingrid Hernandez, R.N., Wayne Rackoff, M.D., Stefan Faderl, M.D., Deborah Thomas, M.D., Alessandra Ferrajoli, M.D., Moshe Talpaz, M.D., Hagop Kantarjian, M.D.

Blood (2004) 104 (11): 1011.

https://doi.org/10.1182/blood.V104.11.1011.1011

Published: 2004

Journal Articles

18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

Elias J. Anaissie, MD, Marisa H. Miceli, MD, Steve D. Strout, Laurie Jones-Jackson, MD, Ronald C. Walker, MD, Gary Purnell, MD, Jose A. Diaz, MD, Fariba Saghafifar, MD, Klaus A. Hollmig, MD, Anasthasios Fassas, MD, Guido Tricot, MD, Bart Barlogie, MD

Blood (2004) 104 (11): 1160.

https://doi.org/10.1182/blood.V104.11.1160.1160

Published: 2004

Journal Articles

The Efficacy and Long-Term Toxicity of Intravenous Busulfan and Cyclophosphamide Conditioning Regimen for Stem Cell Transplantation in Advanced Lymphoma.

Edgardo S. Santos, M.D., Teresa DeCesare, M.D., Mark Goodman, M.D., Joseph D. Rosenblatt, M.D., Denise L. Pereira, M.D., Hugo F. Fernandez, M.D.

Blood (2004) 104 (11): 5215.

https://doi.org/10.1182/blood.V104.11.5215.5215

Published: 2004

Journal Articles

The Diagnostic Value of Gastrointestinal Endoscopy in Anemic Patients with Low Normal Ferritin Level.

Sa Wang, MD, Oluwole Fadare, MD, Anil Nagar, MD, Nelofar Shafi, MD, Michal Rose, MD

Blood (2004) 104 (11): 3209.

https://doi.org/10.1182/blood.V104.11.3209.3209

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism

Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Folate-Dependent Normocytic Anemia Caused By a Hypomorphic Mutation in SLC19A1 gene

Phase I/II Study of Infusional Gemcitabine and High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation for Patients with Relapsed/Refractory Lymphoma: Interim Safety Analysis

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Erlotinib Is Not Effective In Patients (Pts) With JAK-2 V617F Positive Polycythemia Vera

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Infectious Events In Patients with Chronic Myeloid Leukemia Treated with Nilotinib as a Front Line Therapy and After Imatinib Failure

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.

Multiple Myeloma Presenting as Pulmonary, Gastric and Epidural Extramedullary Plasmacytomas: Synchronous Presentation.

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.

18 F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer.

The Efficacy and Long-Term Toxicity of Intravenous Busulfan and Cyclophosphamide Conditioning Regimen for Stem Cell Transplantation in Advanced Lymphoma.

The Diagnostic Value of Gastrointestinal Endoscopy in Anemic Patients with Low Normal Ferritin Level.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only